Search

everythinglearnresearchcommunity

for

Search:↓

Antiandrogens like flutamide are effective in treating conditions like prostate cancer and hair loss, but there's a need for more potent versions. Understanding their structure can help develop better treatments.

Agouti protein affects melanocortin receptors through competitive antagonism and receptor down-regulation.

Potassium channel openers help form elastic fibers in arteries and can treat elastin deficiency and hypertension.

A new treatment for hair loss shows promise with fewer side effects.

Blocking certain proteins can reduce skin inflammation caused by cancer treatment.

New compounds may help treat prostate issues without affecting androgen receptors.

New nonsteroidal molecules can potentially increase dihydrotestosterone in neurons by blocking certain enzymes, without affecting prostate and seminal vesicle weight.

Certain histamine receptors (H2R, H3R, H4R) have unique roles in treating skin diseases, with H2R helping with chronic urticaria and other conditions, H3R providing pain relief and allergy benefits, and H4R reducing inflammation and itchiness.

Combining dutasteride or finasteride with an α1 blocker is more effective for managing BPH than using either alone.

The review suggests that while many AKR1C3 inhibitors show promise for treating certain cancers, more research is needed to confirm their effectiveness in humans.

Alpha-blockers are the most effective and widely used treatment for lower urinary tract symptoms, with minimal side effects.

New compounds with carborane showed anti-androgen effects similar to flutamide.

Some drugs can cause serious side effects like heart issues and nervous system problems, but certain drugs for Parkinson's and overactive bladder may be safer, though they still have some common side effects.

ADT for prostate cancer may harm the heart, but GnRH antagonists might be safer.

New compounds similar to cromakalim were less effective at inhibiting insulin release but improved in solubility and one acted as a calcium entry blocker, not a potassium channel opener.

CRTH2 antagonists might be useful for treating many conditions because they play a role in immune and inflammation responses.

Epirubicin is as effective as doxorubicin for cancer treatment with less heart damage, but doesn't work on doxorubicin-resistant cancers.

New indole-based compounds, particularly cemtirestat, show promise as dual-function drugs for diabetic complications.

A new topical treatment for hair loss shows strong hair growth effects with low toxicity.

Compound 3 protects the heart from damage by activating A1-adenosine receptors.

Some dibenzo compounds might help treat cancer with fewer side effects.

The nature of the side chain in RU 58841 derivatives greatly affects its AR affinity, with the N-(iodopropenyl) derivative 13 showing the highest AR binding affinity, suggesting its potential for developing high-affinity radioiodinated AR radioligands.

New treatments improved blood pressure control in patients with resistant hypertension.

A new compound, 3a, effectively fights prostate cancer better than finasteride.

Triple Hormonal Blockade (ADT3) can effectively manage prostate cancer but requires careful monitoring for heart risks.

Mineralocorticoid receptor antagonist therapy does not significantly reduce mortality in COVID-19 patients.

5-alpha reductase inhibitors slightly reduce urinary symptoms and may lower surgery and acute retention risks in men.

New compounds were made and tested, with compound 6 showing potential for treating prostate-related diseases.